{"id":5809,"date":"2019-01-22T09:00:00","date_gmt":"2019-01-22T09:00:00","guid":{"rendered":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/klinische-trial-van-start-met-ingekapselde-cellen-aan-uz-brussel\/"},"modified":"2024-09-23T11:22:32","modified_gmt":"2024-09-23T11:22:32","slug":"klinische-trial-van-start-met-ingekapselde-cellen-aan-uz-brussel","status":"publish","type":"post","link":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/klinische-trial-van-start-met-ingekapselde-cellen-aan-uz-brussel\/","title":{"rendered":"Klinische trial van start met ingekapselde cellen aan UZ Brussel"},"content":{"rendered":"<p><img loading=\"lazy\" decoding=\"async\" class=\"alignright wp-image-14125\" src=\"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2024\/09\/pec-direct-300x242-1.jpg\" alt=\"\" width=\"450\" height=\"364\" \/>Het Center For Beta Cell Therapy in Diabetes heeft gisteren samen met ViaCyte, Inc. bekend gemaakt aan het UZ Brussel van start te zijn gegaan met klinische trials. Het Center For Beta Cell Therapy in Diabetes is gevestigd in Brussel, en heeft een co\u00f6rdinerende functie in een internationaal consortium over translationele geneeskunde bij diabetes. <strong>Breakthrough T1D is een van de sponsoren van dit consortium en het Center zelf.<\/strong><\/p>\n<p>ViaCyte is een bedrijf dat zich bezig houdt met regeneratieve geneeskunde. ViaCyte ontwikkelt kapsels waarin insulineproducerende cellen verpakt kunnen worden zodat ze veilig kunnen worden ge\u00efmplanteerd.<\/p>\n<p>In deze eerste fase van het klinische onderzoek is bij drie proefpersonen in het UZ Brussel een PEC-Direct implantaat onderhuids geplaatst. Het is de eerste keer dat dit implantaat bij mensen getest wordt. Het PEC-Direct implantaat is een soort theezakje dat 2 cm lang is en gevuld met voorlopercellen. Deze uit menselijke stamcellen afgeleide cellen zullen zich in drie tot zes maanden tijd ontwikkelen tot insulineproducerende b\u00e8tacellen. Omdat het niet gaat om gedoneerde b\u00e8tacellen en de PEC-cellen goed te produceren zijn kunnen de cellen aan het einde van hun levensduur makkelijk worden vervangen. De schaarste aan levensvatbare donorcellen is daarmee ook opgelost.<\/p>\n<div id=\"attachment_14124\" style=\"width: 310px\" class=\"wp-caption alignright\"><img loading=\"lazy\" decoding=\"async\" aria-describedby=\"caption-attachment-14124\" class=\"wp-image-14124 size-medium\" src=\"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2019\/01\/human-beta-cell-implant-300x252-1.png\" alt=\"\" width=\"300\" height=\"252\" \/><p id=\"caption-attachment-14124\" class=\"wp-caption-text\">Menselijk b\u00e8tacelimplantaat bij een type 1 diabetespati\u00ebnt. Insuline-bevattende b\u00e8tacellen zijn rood gekleurd, glucagon-bevattende alfacellen groen en bloedvaten zijn wit.<\/p><\/div>\n<p>Het implantaat is zo gemaakt dat de PEC-Direct cellen toegankelijk zijn voor de bloedtoevoer. Dit betekent echter wel dat vanwege de auto-immuunreactie, gebruikersanti-afstotingsmedicatie zullen moeten nemen. Als behandeling zal het in eerste instantie daarom alleen geschikt zijn voor mensen met diabetes met een hoog risico op acute complicaties.<\/p>\n<p>Deze behandeling kan in de toekomst mogelijk gecombineerd worden metbehandeling van het immuunsysteem om de afweerreactie te voorkomen.<\/p>\n<p>In deze fase van het klinische onderzoek zijn de cellen ingebracht in subtherapeutische hoeveelheid. Er wordt eerst gekeken naar de levensvatbaarheid en ontwikkeling van de voorlopercellen in b\u00e8tacellen in het menselijk lichaam. In een volgende fase van het onderzoek zal worden gekeken naar de insulineproductie van de ontstane cellen.<\/p>\n<p>Het klinische deel van het onderzoek wordt gedaan onder leiding van professor Bart Keymeulen aan de VrijeUniversiteit van Brussel.<\/p>","protected":false,"raw":""},"excerpt":{"rendered":"<p>Het Center For Beta Cell Therapy in Diabetes heeft gisteren samen met ViaCyte, Inc. bekend gemaakt aan het UZ Brussel van start te zijn gegaan met klinische trials. Het Center For Beta Cell Therapy in Diabetes is gevestigd in Brussel, en heeft een co\u00f6rdinerende functie in een internationaal consortium over translationele geneeskunde bij diabetes. Breakthrough [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[184],"tags":[],"class_list":["post-5809","post","type-post","status-publish","format-standard","hentry","category-archief"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.3 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Klinische trial van start met ingekapselde cellen aan UZ Brussel - Breakthrough T1D<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/klinische-trial-van-start-met-ingekapselde-cellen-aan-uz-brussel\/\" \/>\n<meta property=\"og:locale\" content=\"nl_NL\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Klinische trial van start met ingekapselde cellen aan UZ Brussel - Breakthrough T1D\" \/>\n<meta property=\"og:description\" content=\"Het Center For Beta Cell Therapy in Diabetes heeft gisteren samen met ViaCyte, Inc. bekend gemaakt aan het UZ Brussel van start te zijn gegaan met klinische trials. Het Center For Beta Cell Therapy in Diabetes is gevestigd in Brussel, en heeft een co\u00f6rdinerende functie in een internationaal consortium over translationele geneeskunde bij diabetes. Breakthrough [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/klinische-trial-van-start-met-ingekapselde-cellen-aan-uz-brussel\/\" \/>\n<meta property=\"og:site_name\" content=\"Breakthrough T1D\" \/>\n<meta property=\"article:published_time\" content=\"2019-01-22T09:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-09-23T11:22:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2024\/09\/pec-direct-300x242-1.jpg\" \/>\n<meta name=\"author\" content=\"ylt-admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Geschreven door\" \/>\n\t<meta name=\"twitter:data1\" content=\"ylt-admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Geschatte leestijd\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/klinische-trial-van-start-met-ingekapselde-cellen-aan-uz-brussel\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/klinische-trial-van-start-met-ingekapselde-cellen-aan-uz-brussel\/\"},\"author\":{\"name\":\"ylt-admin\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/c141fde9814deb17e9eb392bdb6619a6\"},\"headline\":\"Klinische trial van start met ingekapselde cellen aan UZ Brussel\",\"datePublished\":\"2019-01-22T09:00:00+00:00\",\"dateModified\":\"2024-09-23T11:22:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/klinische-trial-van-start-met-ingekapselde-cellen-aan-uz-brussel\/\"},\"wordCount\":373,\"publisher\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#organization\"},\"image\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/klinische-trial-van-start-met-ingekapselde-cellen-aan-uz-brussel\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2024\/09\/pec-direct-300x242-1.jpg\",\"articleSection\":[\"Archief\"],\"inLanguage\":\"nl-NL\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/klinische-trial-van-start-met-ingekapselde-cellen-aan-uz-brussel\/\",\"url\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/klinische-trial-van-start-met-ingekapselde-cellen-aan-uz-brussel\/\",\"name\":\"Klinische trial van start met ingekapselde cellen aan UZ Brussel - Breakthrough T1D\",\"isPartOf\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/klinische-trial-van-start-met-ingekapselde-cellen-aan-uz-brussel\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/klinische-trial-van-start-met-ingekapselde-cellen-aan-uz-brussel\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2024\/09\/pec-direct-300x242-1.jpg\",\"datePublished\":\"2019-01-22T09:00:00+00:00\",\"dateModified\":\"2024-09-23T11:22:32+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/klinische-trial-van-start-met-ingekapselde-cellen-aan-uz-brussel\/#breadcrumb\"},\"inLanguage\":\"nl-NL\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/klinische-trial-van-start-met-ingekapselde-cellen-aan-uz-brussel\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/klinische-trial-van-start-met-ingekapselde-cellen-aan-uz-brussel\/#primaryimage\",\"url\":\"\",\"contentUrl\":\"\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/klinische-trial-van-start-met-ingekapselde-cellen-aan-uz-brussel\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/breakthrought1d.eu\/nl\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Klinische trial van start met ingekapselde cellen aan UZ Brussel\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#website\",\"url\":\"https:\/\/breakthrought1d.eu\/nl\/\",\"name\":\"Breakthrough T1D\",\"description\":\"Wij zetten ons in voor een toekomst zonder T1D\",\"publisher\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/breakthrought1d.eu\/nl\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"nl-NL\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#organization\",\"name\":\"Breakthrough T1D\",\"url\":\"https:\/\/breakthrought1d.eu\/nl\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2024\/11\/BTlogo.png\",\"contentUrl\":\"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2024\/11\/BTlogo.png\",\"width\":330,\"height\":141,\"caption\":\"Breakthrough T1D\"},\"image\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/c141fde9814deb17e9eb392bdb6619a6\",\"name\":\"ylt-admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/67a3317a8082bc0f586c2e46f82a1617530cf674f2027a1a7d60fdff63a2c3e8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/67a3317a8082bc0f586c2e46f82a1617530cf674f2027a1a7d60fdff63a2c3e8?s=96&d=mm&r=g\",\"caption\":\"ylt-admin\"},\"sameAs\":[\"https:\/\/87.250.144.92\"],\"url\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/author\/ylt-admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Klinische trial van start met ingekapselde cellen aan UZ Brussel - Breakthrough T1D","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/klinische-trial-van-start-met-ingekapselde-cellen-aan-uz-brussel\/","og_locale":"nl_NL","og_type":"article","og_title":"Klinische trial van start met ingekapselde cellen aan UZ Brussel - Breakthrough T1D","og_description":"Het Center For Beta Cell Therapy in Diabetes heeft gisteren samen met ViaCyte, Inc. bekend gemaakt aan het UZ Brussel van start te zijn gegaan met klinische trials. Het Center For Beta Cell Therapy in Diabetes is gevestigd in Brussel, en heeft een co\u00f6rdinerende functie in een internationaal consortium over translationele geneeskunde bij diabetes. Breakthrough [&hellip;]","og_url":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/klinische-trial-van-start-met-ingekapselde-cellen-aan-uz-brussel\/","og_site_name":"Breakthrough T1D","article_published_time":"2019-01-22T09:00:00+00:00","article_modified_time":"2024-09-23T11:22:32+00:00","og_image":[{"url":"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2024\/09\/pec-direct-300x242-1.jpg","type":"","width":"","height":""}],"author":"ylt-admin","twitter_card":"summary_large_image","twitter_misc":{"Geschreven door":"ylt-admin","Geschatte leestijd":"2 minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/klinische-trial-van-start-met-ingekapselde-cellen-aan-uz-brussel\/#article","isPartOf":{"@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/klinische-trial-van-start-met-ingekapselde-cellen-aan-uz-brussel\/"},"author":{"name":"ylt-admin","@id":"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/c141fde9814deb17e9eb392bdb6619a6"},"headline":"Klinische trial van start met ingekapselde cellen aan UZ Brussel","datePublished":"2019-01-22T09:00:00+00:00","dateModified":"2024-09-23T11:22:32+00:00","mainEntityOfPage":{"@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/klinische-trial-van-start-met-ingekapselde-cellen-aan-uz-brussel\/"},"wordCount":373,"publisher":{"@id":"https:\/\/breakthrought1d.eu\/nl\/#organization"},"image":{"@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/klinische-trial-van-start-met-ingekapselde-cellen-aan-uz-brussel\/#primaryimage"},"thumbnailUrl":"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2024\/09\/pec-direct-300x242-1.jpg","articleSection":["Archief"],"inLanguage":"nl-NL"},{"@type":"WebPage","@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/klinische-trial-van-start-met-ingekapselde-cellen-aan-uz-brussel\/","url":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/klinische-trial-van-start-met-ingekapselde-cellen-aan-uz-brussel\/","name":"Klinische trial van start met ingekapselde cellen aan UZ Brussel - Breakthrough T1D","isPartOf":{"@id":"https:\/\/breakthrought1d.eu\/nl\/#website"},"primaryImageOfPage":{"@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/klinische-trial-van-start-met-ingekapselde-cellen-aan-uz-brussel\/#primaryimage"},"image":{"@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/klinische-trial-van-start-met-ingekapselde-cellen-aan-uz-brussel\/#primaryimage"},"thumbnailUrl":"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2024\/09\/pec-direct-300x242-1.jpg","datePublished":"2019-01-22T09:00:00+00:00","dateModified":"2024-09-23T11:22:32+00:00","breadcrumb":{"@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/klinische-trial-van-start-met-ingekapselde-cellen-aan-uz-brussel\/#breadcrumb"},"inLanguage":"nl-NL","potentialAction":[{"@type":"ReadAction","target":["https:\/\/breakthrought1d.eu\/nl\/nieuws\/klinische-trial-van-start-met-ingekapselde-cellen-aan-uz-brussel\/"]}]},{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/klinische-trial-van-start-met-ingekapselde-cellen-aan-uz-brussel\/#primaryimage","url":"","contentUrl":""},{"@type":"BreadcrumbList","@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/klinische-trial-van-start-met-ingekapselde-cellen-aan-uz-brussel\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/breakthrought1d.eu\/nl\/"},{"@type":"ListItem","position":2,"name":"Klinische trial van start met ingekapselde cellen aan UZ Brussel"}]},{"@type":"WebSite","@id":"https:\/\/breakthrought1d.eu\/nl\/#website","url":"https:\/\/breakthrought1d.eu\/nl\/","name":"Breakthrough T1D","description":"Wij zetten ons in voor een toekomst zonder T1D","publisher":{"@id":"https:\/\/breakthrought1d.eu\/nl\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/breakthrought1d.eu\/nl\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"nl-NL"},{"@type":"Organization","@id":"https:\/\/breakthrought1d.eu\/nl\/#organization","name":"Breakthrough T1D","url":"https:\/\/breakthrought1d.eu\/nl\/","logo":{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/logo\/image\/","url":"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2024\/11\/BTlogo.png","contentUrl":"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2024\/11\/BTlogo.png","width":330,"height":141,"caption":"Breakthrough T1D"},"image":{"@id":"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/c141fde9814deb17e9eb392bdb6619a6","name":"ylt-admin","image":{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/67a3317a8082bc0f586c2e46f82a1617530cf674f2027a1a7d60fdff63a2c3e8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/67a3317a8082bc0f586c2e46f82a1617530cf674f2027a1a7d60fdff63a2c3e8?s=96&d=mm&r=g","caption":"ylt-admin"},"sameAs":["https:\/\/87.250.144.92"],"url":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/author\/ylt-admin\/"}]}},"_links":{"self":[{"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/posts\/5809","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/comments?post=5809"}],"version-history":[{"count":1,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/posts\/5809\/revisions"}],"predecessor-version":[{"id":6849,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/posts\/5809\/revisions\/6849"}],"wp:attachment":[{"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/media?parent=5809"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/categories?post=5809"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/tags?post=5809"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}